Abstract
Secoisolariciresinol diglucoside (SDG) from flaxseed has been shown to be effective in preventing/delaying the development of type-1 and type-2 diabetes. The hypoglycemic effect of SDG in type-2 diabetes has been suggested to be due to its antioxidant activity. Hyperglycemia in type-2 diabetes could be due to an increase in the expression of phosphoenolpyruvate carboxykinase (PEPCK), a rate-limiting enzyme in the gluconeogenesis in the liver. It is possible that the hypoglycemic effect of SDG in type-2 diabetes is due to suppression of expression of PEPCK gene. An investigation, therefore, was made on the effect of SDG on the PEPCK gene expression. Primary hepatocyte culture was treated with insulin, a physiological inhibitor of PEPCK gene expression, or with SDG for 12 hours. After RNA extractions, Northern blot analysis was done. SDG in the concentration of 100 µM completely suppressed the expression of PEPCK gene. Insulin in the concentration of 10 nM almost completely suppressed the PEPCK gene expression. The results suggest that SDG suppresses the expression of PEPCK gene and that its known hypoglycemic effect may be due to suppression of PEPCK gene expression.
Article PDF
Avoid common mistakes on your manuscript.
References
Olefsky JM, Ciaraldi TP, Kolterman OG (1985) Mechanism of insulin resistance in non-insulin-dependent (type-2) diabetes. Am J Med 79 (suppl 3B):12–22.
Olefsky JM (1985) Pathogenesis of insulin resistance and hyperglycemia in non-insulin-dependent diabetes mellitus. Am J Med 79 (suppl 3B):1–7.
DeFronzo RA (1988) The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687.
Consoli A, Nurjhan N, Capani F, Gerich J (1989) Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550–557.
Magnusson I, Rothman DL, Katz LD, Shulman RO, Shulman GI (1992) Increased rate of gluconeogenesis in type-2 diabetes mellitus. A13C nuclear magnetic resonance study. J Clin Invest 90:1323–1327.
Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of a new oral antidiabetic agent CS-O45. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558.
Rognstad R (1979) Rate-limiting steps in metabolic pathways. J Biol Chem 254:1875–1878.
Nandan SD, Beale EG (1992) Regulation of phosphoenolpyruvate carboxykinase mRNA in mouse liver, kidney and fat tissues by fasting, diabetes and insulin. Lab Anim Sci 42:473–477.
Veneziale CM, Donofrio JC, Nishimura H (1983) The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. J Biol Chem 258:14257–14262.
Chang AY, Schneider D (1970) Abnormalities in hepatic enzyme activities during development of diabetes in db mice. Diabetologia 6:274–278.
Shargo E, Lardy HA, Nordlie RC, Fraser DO (1963) Metabolic and hormonal control of phosphoenolpyruvate carboxykinase and malic enzyme in rat liver. J Biol Chem 238:3188–3192.
Loose DS, Wynshaw-Boris A, Meisner HM, Dod Y, Hanson RW (1985) Hormonal regulation of phosphoenolpyruvate carboxykinase gene expression. In: Molecular basis of insulin action. Czech MP (ed.) Plenum:New York, pp 347–368.
Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661–1669.
Davies GF, Khandelwal RL, Roesler WJ (1999) Troglitazone inhibits expression of phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Biochem Biophys Acta 1451:122–131.
Davies GF, Khandelwal RL, Wu L, Juurlink BHJ, Roesler WJ (2001) Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-γ (PPAR γ)-independent, antioxidant-related mechanism. Biochem Pharmacol 62:1071–1079.
Prasad K (1997) Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flaxseed. Mol Cell Biochem 168:117–123.
Prasad K (2000) Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Intl J Angiol 9:220–225.
Prasad K, Mantha SV, Muir AD, Westcott ND (2000) Protective effect of secoisolariciresinol diglucoside against streptozotocin-induced diabetes and its mechanism. Mol Cell Biochem 206:141–150.
Prasad K (2000) Oxidative stress as a mechanism of diabetes in diabetic prone BB rats: effects of secoisolariciresinol diglucoside (SDG). Mol Cell Biochem 209:89–96.
Prasad K (2001) Secoisolariciresinol diglucoside from flaxseed delays the development of type-2 diabetes in Zucker rat. J Lab Clin Med 138:32–39.
Cascales C, Mangiapane EH, Brindley DN (1984) Oleic acid promotes the activation and translocation of phosphatidate phosphohydrolase from the cytosol to particulate fractions of isolated rat hepatocytes. Biochem J 219:911–916.
Hanson RW, Patel YM (1994) Phosphoenolpyruvate carboxykinase (GTP): the gene and the enzyme. Adv Enzymol Relat Areas Mol Biol 69:203–281.
Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komoda T (1997) Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 235:113–116.
Burton GW, Traber MG (1990) Vitamin E:antioxidant activity, biokinetics, and bioavailability. Ann Rev Nutr 10:357–382.
Author information
Authors and Affiliations
About this article
Cite this article
Prasad, K. Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new antidiabetic agent. International Journal of Angiology 11, 107–109 (2002). https://doi.org/10.1007/BF01616377
Issue Date:
DOI: https://doi.org/10.1007/BF01616377